Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a ...
Moderna reported a bigger-than-expected quarterly loss on Friday, hit by a charge related to its efforts to scale down ...
Moderna CEO Stéphane Bancel deflected concerns about the new presidential administration's potential impact on life sciences ...
A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological ...
The vaccine maker Moderna had no Valentine’s Day chocolates for investors when its fourth-quarter financial results came out ...
Moderna (MRNA) said that the two-season Phase 3 study evaluating the efficacy, safety and immunogenicity of Moderna’s trivalent vaccine against ...
Moderna Inc.’s stock erased early losses to gain 3.4% on Friday, after the biotech company posted a wider-than-expected ...
Moderna reported a Q4 EPS loss of $2.91, missing estimates, with revenue down 66% YoY to $966 million. The company reaffirmed ...
Moderna Inc. recorded another quarterly loss as vaccine sales wane and the company had an unexpected charge for a canceled manufacturing contract.
Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...
Among the handful of drugmakers to advance a successful COVID-19 vaccine in 2020, Moderna—whose mRNA shot Spikevax was also ...
It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the ...